Sulforaphane induces cell cycle arrest and apoptosis in murine osteosarcoma cells in vitro and inhibits tumor growth in vivo

Oncology Reports

Volumn 18, Issue 5, 2007, Pages 1263-1268

  Matsui, Taka Aki ^a   Murata, Hiroaki ^a   Sakabe, Tomoya ^a   Sowa, Yoshihiro ^a   Horie, Naoyuki ^a   Nakanishi, Ryoko ^a   Sakai, Toshiyuki ^a   Kubo, Toshikazu ^a  

^a KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

Author keywords

Apoptosis; Cell cycle arrest; Osteosarcoma; Sulforaphane; Xenografts

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLIN DEPENDENT KINASE INHIBITOR 1A; SULFORAFAN; THIOCYANIC ACID DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL; APOPTOSIS; ARTICLE; BAGG ALBINO MOUSE; BONE TUMOR; CELL CYCLE G2 PHASE; CELL DIVISION; DRUG EFFECT; HUMAN; MALE; METABOLISM; MOUSE; OSTEOSARCOMA; PATHOLOGY;

ANIMALS; ANTICARCINOGENIC AGENTS; APOPTOSIS; BONE NEOPLASMS; CELL DIVISION; CYCLIN-DEPENDENT KINASE INHIBITOR P21; G2 PHASE; HUMANS; MALE; MICE; MICE, INBRED BALB C; OSTEOSARCOMA; THIOCYANATES;

EID: 38449089515     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.18.5.1263     Document Type: Article

References (46)

1. Unni KK: Dahlin's Bone Tumors. In: General Aspects and Data on 11,087 Cases. 5th Edition, Lippincott-Raven, Philadelphia, pp143-183, 1996.
2. Meyers PA, Heller G, Healey J, Huvos A, Lane J, Marcove R, Applewhite A, Vlamis V and Rosen G: Chemotherapy for nonmetastatic osteogenic sarcoma: the Memorial Sloan-Kettering experience. J Clin Oncol 10: 5-15, 1992.
3. Bramwell VH, Burgers M, Sneath R, Souhami R, van Oosterom AT, Voute PA, Rouesse J, Spooner D, Craft AW, Somers R, Pringle J, Malcolm AJ, Eijken J, Thomas D, Uscinska B, Machin D and Glabbeke M: A comparison of two short intensive adjuvant chemotherapy regimens in operable osteosarcima of limbs in children and young adults: the first study of the European Osteosarcoma Intergroup. J Clin Oncol 10: 1579-1591, 1992. (Pubitemid 23057988)
4. Patel SJ, Lynch JW Jr, Jhonson T, Carroll RR, Schumacher C, Spanier S and Scarborough M: Dose-intense ifosfamide/doxorubicin/cisplatin based chemotherapy for osteosarcoma in adults. Am J Clin Oncol 25: 489-495, 2002. (Pubitemid 35154956)
5. Zalupski MM, Rankin C, Ryan JR, Lucas DR, Muler J, Lanier KS, Budd GT, Biermann JS, Meyers FJ and Antman K: Adjuvant therapy of osteosarcoma - A phase II trial: Southwest Oncology Group study 9139. Cancer 100: 818-825, 2004. (Pubitemid 38176862)
6. Marina NM, Pratt CB, Rao BN, Shema SJ and Meyer WH: Improved prognosis of children with osteosarcoma metastatic to the lung(s) at the time of diagnosis. Cancer 70: 2722-2727, 1992.
7. Voute PA, Souhami RL, Nooij M, Somers R, Cortes-Funes H, van der Eijken JW, Pringle J, Hogendoorn PC, Kirkpatrick A, Uscinska BM, van Glabbeke M, Machin D and Weeden S: A phase II study of cisplatin, ifosfamide and doxorubicin in operable primary, axial skeletal and metastatic osteosarcoma. European Osteosarcoma Intergroup (EOI). Ann Oncol 10: 1211-1218, 1999. (Pubitemid 29533572)
8. Ozaki T, Flege S, Kevric M, Lindner N, Maas R, Delling G, Schwarz R, von Hochstetter AR, Salzer-Kuntschik M, Berdel WE, Jurgens H, Exner GU, Reichardt P, Mayer-Steinacker R, Ewerbeck V, Kotz R, Winkelmann W and Bielack SS: Osteosarcoma of the pelvis: experience of the Cooperative Osteosarcoma Study Group. J Clin Oncol 21: 334-341, 2003. (Pubitemid 46613482)
9. Bacci G, Briccoli A, Rocca M, Ferrari S, Donati D, Longhi A, Bertoni F, Bacchini P, Giacomini S, Forni C, Manfrini M and Galletti S: Neoadjuvant chemotherapy for osteosarcoma of the extremities with metastases at presentation: recent experience at the Rizzoli Institute in 57 patients treated with cisplatin, doxorubicin and a high dose of methotrexate and ifosfamide. Ann Oncol 14: 1126-1134, 2003. (Pubitemid 36950179)
10. Patel SR, Papadopolous N, Raymond AK, Donato M, Seong CM, Yasko AW, Lewis VO, Lin PP, Champlin R and Benjamin RS: A phase II study of cisplatin, doxorubicin and ifosfamide with peripheral blood stem cell support in patients with skeletal osteosarcoma and variant bone tumors with a poor prognosis. Cancer 101: 156-163, 2004. (Pubitemid 38812435)
11. Takeshita H, Gebhardt MC, Springfield DS, Kusuzaki K and Mankin HJ: Experimental models for the study of drug resistance in osteosarcoma: P-glycoprotein-positive, murine osteosarcoma cell lines. J Bone Joint Surg 78-A: 366-375, 1996.
12. Hirata M, Kusuzaki K, Takeshita H, Hashiguchi S, Hirasawa Y and Ashihara T: Drug resistance modification using pulsing electromagnetic field stimulation for multidrug resistant mouse osteosarcoma cell line. Anticancer Res 21: 317-320, 2001. (Pubitemid 32267661)
13. Webster KR: The therapeutic potential of targeting the cell cycle. In: Expert Opin Investig Drugs 7: 865-887, 1998.
14. Schwartz GK and Shah MA: Targeting the cell cycle: a new approach to cancer therapy. J Clin Oncol 23: 9408-9421, 2005.
15. Harper JW, Adami GR, Wei N, Keyomarsi K and Elledge SJ: The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell 75: 805-816, 1993. (Pubitemid 23346377)
16. Dulic V, Kaufmann WK, Wilson SJ, Tlsty TD, Lees E, Harper JW, Elledge SJ and Reed SI: p53-dependent inhibition of cyclin-dependent kinase activities in human fibroblasts during radiation-induced G1 arrest. Cell 76: 1013-1023, 1994. (Pubitemid 24106382)
17. 2/M arrest after DNA damage. J Biol Chem 276: 42971-42977, 2001.
18. 2/M promotes cyclin B-Cdc2 kinase activity. Mol Cell Biol 25: 3364-3387, 2005.
19. Matsumoto T, Sowa Y, Ohtani-Fujita N, Tamaki T, Takenaka T, Kuribayashi K and Sakai T: p53-independent induction of WAF1/Cip1 is correlated with osteoblastic differentiation by vitamin D3. Cancer Lett 129: 61-68, 1998. (Pubitemid 28375239)
20. Gartel AL, Serfas MS and Tyner AL: p21-negative regulator of the cell cycle. Proc Soc Exp Biol Med 213: 138-149, 1996.
21. MacKeigan JP, Murphy LO and Bleins J: Sensitized RNAi screen of human kinases and phosphatases identifies new regulators of apoptosis and chemoresistance. Nat Cell Biol 7: 591-600, 2005. (Pubitemid 40796982)
22. Zhang Y, Talalay P, Cho CG and Posner GH: A major inducer of anticarcinogenic protective enzymes from broccoli: isolation and elucidation of structure. Proc Natl Acad Sci USA 89: 2399-2403, 1992.
23. Zhang Y, Kensler TW, Cho CG, Posner GH and Talalay P: Anticarcinogenic activities of sulforaphane and structurally related synthetic norbornyl isothiocyanates. Proc Natl Acad Sci USA 91: 3147-3150, 1994. (Pubitemid 24130192)
24. Fahey JW, Zhang Y and Talalay P: Broccoli sprouts: an exceptionally rich source of inducers of enzymes that protect against chemical carcinogens. Proc Natl Acad Sci USA 94: 10367-10372, 1997. (Pubitemid 27407048)
25. Chung FL, Conaway CC, Rao CV and Reddy BS: Chemoprevention of colonic aberrant crypt foci in Fischer rats by sulforaphane and phenetyl isothiocyanate. Carcinogenesis 21: 2287-2291, 2000. (Pubitemid 32049237)
26. Fahey JW, Haristoy X, Dolan PM, Kensler TW, Scholtus I, Stephenson KK, Talalay P and Lozniewski A: Sulforaphane inhibits extracellular, intracellular and antibiotic-resistant strains of Helicobacter pylori and prevents benzo (a) pyrene-induced stomach tumors. Proc Natl Acad Sci USA 99: 7610-7615, 2002. (Pubitemid 34568739)
27. Singh AV, Xiao D, Lew KL, Dhir R and Singh SV: Sulforaphane induces caspase-mediated apoptosis in cultured PC-3 human prostate cancer cells and retards growth of PC-3 xenografts in vivo. Carcinogenesis 25: 83-90, 2004. (Pubitemid 38128621)
28. Jackson SJT and Singletary KW: Sulforaphane: a naturally occurring mammary carcinoma mitotic inhibitor, which disrupts tubulin polymerization. Carcinogenesis 25: 219-227, 2004. (Pubitemid 38239805)
29. Gamet-Payrastre L, Li P, Lumeau S, Cassar G, Dupont MA, Chevolleau S, Gasc N, Tulliez J and Terce F: Sulforaphane, a naturally occurring isothiocyanate, induces cell cycle arrest and apoptosis in HT29 human colon cancer cells. Cancer Res 60: 1426-1433, 2000. (Pubitemid 30152017)
30. Fimognari C, Nusse M, Cesari R, Iori R, Cantelli-Forti G and Hrelia P: Growth inhibition, cell-cycle arrest and apoptosis in human T-cell leukemia by the isothiocyanate sulforaphane. Carcinogenesis 23: 581-586, 2002. (Pubitemid 34498494)
31. Parnaud G, Li P, Cassar G, Rouimi P, Tulliez J, Combaret L and Gamet-Payrastre L: Mechanism of sulforaphane-induced cell cycle arrest and apoptosis in human colon cancer cells. Nutr Cancer 48: 198-206, 2004. (Pubitemid 39045782)
32. 2-M phase cell cycle arrest involves checkpoint kinase 2-mediated phosphorylation of cell division cycle 25C. J Biol Chem 279: 25813-25822, 2004.
33. Matsui TA, Sowa Y, Yoshida T, Murata H, Horinaka M, Wakada M, Nakanishi R, Sakabe T, Kubo T and Sakai T: Sulforaphane enhances TRAIL-induced apoptosis through the induction of DR5 expression in human osteosarcoma cells. Carcinogenesis 27: 1768-1777, 2006. (Pubitemid 44288659)
34. Asai T, Ueda T, Itoh K, Yoshioka K, Aoki Y, Mori S and Yoshikawa H: Establishment and characterization of a murine osteosarcoma cell line (LM8) with high metastatic potential to the lung. Int J Cancer 76: 418-422, 1998. (Pubitemid 28282943)
35. Nakano K, Mizuno T, Sowa Y, Orita T, Yoshino T, Okuyama Y, Fujita T, Ohtani-Fujita N, Matsukawa Y, Tokino T, Yamagishi H, Oka T, Nomura H and Sakai T: Butyrate activates the WAF1/Cip1 gene promoter through Sp1 sites in a p53-negative human colon cancer cell line. J Biol Chem 272: 22199-22206, 1997. (Pubitemid 27382850)
36. Nakata S, Yoshida T, Horinaka M, Shiraishi T, Wakada M and Sakai T: Histone deacetylase inhibitors up-regulate death receptor 5/TRAIL-R2 and sensitize apoptosis induced by TRAIL/APO2-L in human malignant tumor cells. Oncogene 23: 6261-6271, 2004. (Pubitemid 39215296)
37. Singh SV, Mohan RR, Agarwal R, Benson PJ, Hu X, Rudy MA, Xia H, Katoh A, Srivastava SK, Mukhtar H, Gupta V and Zaren HA: Novel anti-carcinogenic activity of an organosulfide from garlic: inhibition of H-RAS oncogene-transformed tumor growth in vivo by diallyl disulfide is associated with inhibition of p21H-ras processing. Biochem Biophys Res Commun 225: 660-665, 1996. (Pubitemid 26355654)
38. Shen G, Xu C, Chen C, Hebbar V and Kong AN: p53-independent G1 cell cycle arrest of human colon carcinoma cells HT-29 by sulforaphane is associated with induction of p21CIP1 and inhibition of expression of cyclin D1. Cancer Chemother Pharmacol 57: 317-327, 2006.
39. Lowe SW, Ruley HE, Jacks T and Housman DE: p53-dependent apoptosis modulates the cytotoxicity of anticancer drugs. Cell 74: 957-967, 1993. (Pubitemid 23289454)
40. Wang LH, Okaichi K, Ihara M and Okumura Y: Sensitivity of anticancer drugs in Saos-2 cells transfected with mutant p53 varied with mutation point. Anticancer Res 18: 321-325, 1998. (Pubitemid 28174726)
41. Choi S and Singh SV: Bax and Bak are required for apoptosis induction by sulforaphane, a cruciferous vegetable-derived cancer chemopreventive agent. Cancer Res 65: 2035-2043, 2005. (Pubitemid 40478634)
42. Kim K, Kim EH, Eom YW, Kim WH, Kwon TK, Lee SJ and Choi KS: Sulforaphane sensitizes tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-resistant hepatoma cells to TRAIL-induced apoptosis through reactive oxygen speciesmediated up-regulation of DR5. Cancer Res 66: 1740-1750, 2006. (Pubitemid 43259959)
43. Ye L, Dinkova-Kostova AT, Wade KL, Zhang Y, Shapiro TA and Talalay P: Quantitative determination of dithiocarbamates in human plasma, serum, erythrocytes and urine: pharmacokinetics of broccoli sprout isothiocyanates in humans. Clin Chim Acta 316: 43-53, 2002. (Pubitemid 34028187)
44. Hu R, Hebbar V, Kim BR, Chen C, Winnik B, Buckley B, Soteropoulos P, Tolias P, Hart RP and Kong AN: In vivo pharmacokinetics and regulation of gene expression profiles by isothiocyanate sulforaphane in the rat. J Pharmacol Exp Ther 310: 263-271, 2004. (Pubitemid 38812720)
45. Myzak MC, Karplus PA, Chung FL and Dashwood RH: A novel mechanism of chemoprotection by sulforaphane: inhibition of histone deacetylase. Cancer Res 64: 5767-5774, 2004. (Pubitemid 39095576)
46. Myzac MC, Hardin K, Wang R, Dashwood RH and Ho E: Sulforaphane inhibits histone deacetylase activity in BPH-1, LnCaP and PC-3 prostate epithelial cells. Carcinogenesis 27: 811-819, 2006. Technology